Switching to doravirine in cART experienced patients: An effective and highly tolerated option with substantial cost savings.
Vincent R LantingPiter OosterhofDaoud Ait MohaRoos van HeerdeMarie José T KleeneJanneke E StalenhoefMarieke J A de RegtSaskia M E VrouenraetsGuido E L van den BerkKees Brinkmannull nullPublished in: Journal of acquired immune deficiency syndromes (1999) (2023)
This study demonstrated that switching to a doravirine-based regimen, mostly DOR/TDF/3TC, was highly effective and generally well tolerated, with substantial cost savings.